ALNY Q3 revenues | ABUS Message Board Posts


Arbutus Biopharma

  ABUS website

  • Please accept my sincerest apologies for failing to publicly acknowledge our fallen heroes this past Memorial Day. No excuse I could offer could justify the oversight. Along with you, I salute the many men and women who have proudly and selflessly served in our military to protect, defend and secure the freedoms and liberties we enjoy each and every day. Their bravery in making the ultimate sacrifice will forever be appreciated and they will always be remembered and celebrated and never taken for granted or forgotten.


ABUS   /  Message Board  /  Read Message

 
BOARD

GROUPS
 










Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message board, top of board
Msg  35172 of 35175  at  10/27/2022 10:38:45 AM  by

Steve_382


ALNY Q3 revenues

 I posted this on the ALNY  board, but thought the Onpattro numbers would be of interest to ABUS holders also.
 

Q3 Results

FWIW, this is a pic of my product revenue table. Yellow highlights are still estimates. Notably, Onpattro patients are starting to move to Amvuttra. Leqvio is still just my guess on the numbers, but NVS reported $34M in sales, so that's about 10,000 patients. Givlaari was basically flat Q/Q. No guarantees on the numbers, but I tried.
 


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 2  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message board, top of board




Financial Market Data provided by
.
Loading...